GLP-1tirzepatideglp-1diabetic-retinopathyophthalmology

Correspondence questions tirzepatide ocular outcomes study in Ophthalmology Retina

Guang and colleagues write in response to Hong et al.'s comparison of eye outcomes between tirzepatide and GLP-1 receptor agonists in type 2 diabetes.

By Maren Holt · Senior Reporter, GLP-1

Oct 6 20:00 ETSource: Ophthalmology. Retina

The wire

01A letter published October 7 in Ophthalmology Retina responds to Hong et al.'s study of ocular outcomes with tirzepatide versus GLP-1 receptor agonists in type 2 diabetes.
02Retinal safety of incretin drugs remains an open question for clinicians prescribing tirzepatide to patients with diabetic retinopathy risk.
03The item is correspondence rather than new data; the specific methodological objections and any author reply are not detailed in the available text.

From the source

Re: Hong et al.: Ocular Outcomes with Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes (Ophthalmol Retina. 2026;10:625-632)
Ophthalmology. Retina · 2026 Oct 7 · Guang X, Zhang G, Wang Y et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42848353/